The Effect of Parenteral or Oral Iron Supplementation on Fatigue, Sleep, Quality of Life and Restless Legs Syndrome in Iron Deficient Blood Donors: A Secondary Analysis of the Ironwoman Rct

Susanne Macher, MD,1 Cornelia Herster, MD,1 Magdalena Holter, BSc,2 Martina Moritz, MD,1 Eva Maria Matzhold, PhD,1 Tatjana Stojakovic, MD,3 Thomas R. Pieber, MD,4 Peter Schlenke, MD,1 Camilla Drexler, MD,1+ Karin Amrein, MD and MSc4*

1Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria; 2Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Austria; 3University Hospital Graz, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Graz, Austria; 4Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria;

* Correspondence: karin.amrein@medunigraz.at

Abstract:

Background: Besides anemia, iron deficiency may cause more subtle symptoms including those of the restless legs syndrome (RLS), the chronic fatigue syndrome (CFS) or sleeping disorders.

Objective: The aim of this pre-planned secondary analysis was to compare the frequency and severity of symptoms associated with iron deficiency before and after (intravenous or oral) iron supplementation in iron deficient blood donors.

Methods/Design: Prospective, randomized, controlled, single centre trial. (ClinicalTrials.gov: NCT01787526).

Setting: Tertiary care center in Graz, Austria

Participants: 138 female and 38 male whole blood and platelet apheresis donors aged ≥18 and ≤65 years with iron deficiency (ferritin ≤30ng/ml at the time of blood donation).

Interventions: Intravenous iron (1 g ferric carboxymaltose, n=86) or oral iron supplementation (10 g iron fumarate, 100 capsules, n=90).

Measurements: Clinical symptoms were evaluated by a survey before iron therapy (visit 0, V0) and after 8-12 weeks (visit 1, V1) including questions about symptoms of RLS, CFS, sleeping disorders, quality of life and symptoms like headaches, dyspnoea, dizziness, palpitations, pica and trophic changes of fingernails or hair.

Results: We found a significant improvement in the severity of symptoms for RLS, fatigue and sleep quality (p<0.001). Furthermore, a significant decrease of headaches, dyspnoea, dizziness and palpitations was reported (p<0.05). There was no difference between the type of iron supplementation (intravenous versus oral) and clinical outcome data.

Conclusion: Iron supplementation in iron deficient blood donors may be an effective strategy to improve symptoms related to iron deficiency and the wellbeing of blood donors.

Keywords: Iron deficiency; blood donor; fatigue; RLS; iron supplementation
1. Introduction

An imbalance between iron requirements and iron supply results in iron deficiency (ID), the most prevalent nutritive disorder worldwide. It is estimated that two billion people are affected and iron deficiency is the main cause for anemia besides other nutritional causes including vitamin B12 and folate deficiency. Besides anemia, iron deficiency may have other, more subtle adverse effects on an individual such as a restless legs syndrome (RLS), one of the most prevalent neurologic diseases with different symptoms including an urge to move the legs, sometimes accompanied with unpleasant sensations, worsening at rest, and improving with movement, a chronic fatigue syndrome (CFS) or decreased physical and cognitive performance, especially in children and premenopausal women. Furthermore, iron deficiency is associated with sleeping disorders, trophic changes of fingernails and hair, symptoms of pica and obstetric complications including low birth weight, preterm delivery and stillbirth.

As the largest part of total body iron is bound to hemoglobin in red cells, each whole blood donation (about 500 ml) results in an iron loss of 200 to 300 mg and each apheresis donation (plasma, platelets) in a loss of 20 to 25 mg. Given the maximum number of donations per year (e.g. in Austria 4-6 whole blood donations, up to 26 platelet or 45 plasma donations), blood donations may substantially compromise the iron store of individual donors who are indeed often iron deficient.

In the IronWoMan trial, we randomized iron deficient blood donors to a single high dose of intravenous ferric carboxymaltose or to oral iron for 10 weeks. In this pre-planned secondary analysis, we aimed to assess the prevalence and severity of different clinical symptoms related to iron deficiency before and after iron therapy with intravenous or oral iron.

2. Materials and Methods

The study was carried out according to GCP guidelines and conformed to the Declaration of Helsinki. The protocol was approved by the Austrian Agency for Health and Food Safety (AGES) and by the Ethical Committee of the Medical University of Graz. It was registered at the European Clinical Trials Database (EudraCT no. 2013-000327-14) and ClinicalTrials.gov (NCT01787526).

2.1. Donor characteristics:

The study population consisted of healthy male and female whole blood and platelet apheresis donors aged ≥18 and ≤65 years, fulfilling the Austrian criteria for blood donation, with iron deficiency (ferritin level ≤30 ng/ml) but without anemia at the time of blood donation. Exclusion criteria were hemochromatosis, acute infection, pregnancy or lactation, a history of anaphylaxis to intravenous iron or other substances, and signs or symptoms suggestive for acute or chronic gastrointestinal or excessive gynecological bleeding.

2.2. Study design:

The clinical trial was a prospective, randomized, controlled single center study. Recruitment started in June 2014 and was completed in June 2016. The detailed study protocol was previously published. In brief, ferritin screening was done from remaining serum for routine infectious disease testing in donors who had given general informed consent to participate in clinical studies. Donors with a serum ferritin ≤30 ng/ml were invited by telephone to participate in the study in the apheresis unit of the Department of Blood Group Serology and Transfusion Medicine. Before the first visit, a participant code was generated and a randomization for either intravenous (IV) or oral iron was performed.
During the first visit (visit 0, V0), written informed consent was obtained, inclusion/exclusion criteria were checked and a pregnancy test in premenopausal women was performed.

A case report form was filled out by the study participants including questions about:
- Symptoms of the restless legs syndrome (RLS)
- Symptoms of the chronic fatigue syndrome (CFS)
- Sleeping behaviour
- Subjective physical, psychological health and quality of life (QOL)
- Trophic changes of fingernails or hair
- Symptoms of pica

The questions were developed based on published criteria for RLS, fatigue, and sleeping behaviour and also included questions on symptoms known to be associated with iron deficiency such as pica.

The study participants received either a single dose of IV ferric carboxymaltose (1 g in a short infusion, Ferinject®, manufacturer Vifor Pharma, Austria) or 100 capsules of oral ferrous fumarate in combination with ascorbic acid given over 8-12 weeks (each capsule containing 100 mg of bivalent iron and 20 mg ascorbic acid, Ferretab® capsules, manufacturer G.L. Pharma GmbH, Austria; total dose 10 g, assuming a 10% resorption rate).

At visit 1 (V1) after 8 to 12 weeks, the participants completed a second questionnaire containing additional questions about adverse events and compliance with study medication. After V1, all biochemical results were summarized in a written report for each study participant and were sent by mail (including recommendations in case of specific findings).

A schematic study flowchart is given in Figure 1.

**Restless legs syndrome:**
RLS was assumed when the three specific RLS questions of the questionnaire were answered with “Yes” by the study participant. Adapted from the essential diagnostic criteria by Allen et al, we asked 1) for uncomfortable sensations in the legs accompanied by an urge to move the legs, 2) if the urge to move or unpleasant sensations begin or worsen during periods of rest and relieve by movement and 3) if the urge to move or the unpleasant sensations are worse in the evening or night or during the day. Additionally we asked how often the symptoms occurred.

**Fatigue:**
Based on the Multidimensional Fatigue Symptom Inventory (MFSI), 5 different scales (general, physical, emotional, mental, vigor) were evaluated in the questionnaire.

**Quality of sleep:**
To evaluate the quality of sleep, we used the Jenkins Sleep Evaluation Questionnaire and classified the answers with the Jenkins Scale. In the questionnaire we asked how often during the previous four weeks the following symptoms occurred: 1) difficulty falling asleep, 2) waking up several times per night, 3) difficulty staying asleep, and 4) waking up feeling tired and worn out after usual amount of sleep. For every question there was a 6-point response scale.

**Different symptoms:**
Further different questions (i.e. hair loss, brittle nails, headaches) were asked with the possibility to answer with “Yes” or “No”.

The study participants subjectively indicated their quality of life with 5 differences on a Likert type style scale ranging in five steps between “very poor” and “very good”.

2.3. Statistical analysis:

This analysis followed the intention-to-treat principle. Descriptive statistics of the data are presented as median and quartile or absolute and relative frequencies, depending on the type of data. Differences between V0 and V1 are analyzed either by the Wilcoxon signed-rank test or by the McNemar’s test. The significance level was set to alpha=0.05. SPSS statistical software (version 25.0; IBM Corp, Armonk, NY, USA) was used to perform the statistical data analysis. Since the questionnaires used in this study were translated by the study team, their structure was examined before further use. Usability of each questionnaire was evaluated by factorial structure (confirmatory factor analysis) and fit indices. Only questionnaires which met the criteria were analyzed. These analyses were performed with R software (version 3.5.0) using the package “Multidimensional Item Response Theory, mirt”.

3. Results

Between June 2014 and June 2016, a total of 467 blood donors (370 women, 97 men) with a serum ferritin ≤30 ng/ml were invited to participate in the study. 291 declined to participate and 176 were included (138 women, 78%, 38 men, 22%). Total study duration for each participant was 8 to 12 weeks. In August 2016, the last participant completed the study. Demographic data of the study participants are presented in Table 1.

Table 1. Basic characteristics of the study participants (IV, study group with intravenous iron; PO, study group with oral iron; SD standard deviation).

| Type of donor          | Women | Men | Total |
|------------------------|-------|-----|-------|
| Whole blood            | 126   | 31  | 157   |
| Platelet (apheresis)   | 12    | 7   | 19    |
| Study group            |       |     |       |
| IV                     | 69    | 17  | 86    |
| PO                     | 69    | 21  | 90    |
| Sum                    | 138   | 38  | 176   |

| Donor Characteristics  |       |     |       |
|------------------------|-------|-----|-------|
| Age, mean (SD), years  | 36 (13)| 46 (13)| |
| Weight, mean (SD), kg  | 69 (11)| 82 (16)| |
| Body mass index, mean (SD) | 24 (4) | 26 (4) | |
| Total calculated blood volume, mean (SD), liters | 4.0 (0.3) | 5.3 (0.6) | |

The primary hypothesis of the study was that intravenous iron is superior to oral iron in improving iron stores. The primary endpoint of the study was the difference of the transferrin saturation after iron therapy between the two treatment groups. All the biochemical data have been published previously. In brief, the primary endpoint, transferrin saturation, was significantly higher after IV iron (27 [23-35]%, vs. 21 [16-32]% compared to PO; p<0.001), as was the ferritin level.
(IV 105 [75-145] vs. PO 25 [17-34] ng/mL; p<0.001). Anemia was present in 75% of all donors at V0. After IV or oral iron, hemoglobin levels were similar (IV 13.6 [13.0-14.4] vs. PO 13.6 [13.0-14.2] g/dL). Four patients (all in the oral iron group) were lost to follow-up. Participants recommended both treatments (IV 91% vs. PO 79%) and adherence was excellent in both groups (IV 100%, PO 95% who took >90 capsules). The frequency of adverse effects was comparable (38% in both groups) and no serious adverse events occurred.

3.1. Clinical Outcomes:

3.1.1. Restless legs syndrome

At baseline, 19.9% (31/156) and after iron therapy, 17.1% (26/152) of the participants fulfilled the diagnostic criteria for having a RLS. Eighteen study participants fulfilled the diagnostic criteria at both visits and 13 participants fulfilled the criteria only at V0 and not at V1.

Comparing the frequency of symptoms of the 18 study participants plus the 13 participants with RLS only at V0, a significant improvement of RLS symptoms between baseline and after IV or oral iron was determined (p<0.001). Results are shown in Figure 2.

![Figure 2](image)

**Figure 2.** Bar diagram showing the number of study participants (x-axis) who indicate the frequency of their restless legs syndrome (RLS) at the two time points before (V0, dark bars) and after IV or oral iron therapy (V1, bright bars) on the y-axis. The decrease of the RLS occurrence between V0 and V1 was statistically significant (p=0.001, n=31).

3.1.2. Fatigue

Each of the five scales (general, physical, emotional, mental, vigor) and the global evaluation for fatigue improved significantly after iron therapy (p<0.001). Results are shown in Figure 3.
Figure 3. Comparison of median and 1st/3rd quartiles for the fatigue scales before (V0) and after (V1) IV or oral iron therapy. For the 4 scales general, physical, emotional and mental a lower level indicates an improvement, for the scale vigor a higher level indicates an improvement (* p<0.001 for all, n=160).

3.1.3. Quality of sleep

For all 4 qualities of sleep, there was a statistically significant improvement after iron therapy (p<0.05). Results are shown in Figure 4.
before (V0, dark bars) and after iron therapy (V1, bright bars). For all 4 quality of sleep items there was a statistically significant improvement between V0 and V1 (p<0.05 for all, n=160).

3.1.4. Different symptoms

The presence of different symptoms possibly related to iron deficiency at the two visits (ie. brittle nails, hair loss, pica etc.) is shown in Figure 5.

![Figure 5](image-url)

**Figure 5.** Bar diagram indicating the percentage of study participants on the x-axis with the appropriate symptoms indicated on the y-axis before (V0, dark bars) and after iron therapy (V1, bright bars). (* p=0.02, ** p=0.005, *** p<0.001, n=161 - 165).

Between V0 and V1 no difference was seen for the subjective assessment of quality of life (Figure 6).
Figure 6. Bar diagram indicating the percentage of study participants (x-axis) rating the quality of their life between very poor and very good (y-axis) before (V0, dark bars) and after iron therapy (V1, bright bars). (no statistically significant differences, n=168).

3.1.5. Further results – type of iron treatment and ferritin levels at visit 1

There was no significant difference between IV and oral iron therapy for all reported outcomes (data not shown). There was also no significant difference between subgroups with lower or higher ferritin levels at visit 1 (data not shown).

4. Discussion

Besides anemia, iron deficiency may have more subtle adverse effects. In this pre-planned secondary analysis of the IronWoMan RCT testing high-dose IV iron vs. a standard oral regime in iron deficient blood donors, we aimed to evaluate if symptoms known to be associated with iron deficiency improved after iron supplementation.

4.1. Restless legs syndrome (RLS)

RLS is one of the most prevalent neurologic diseases. An association between RLS and iron deficiency has been proposed and iron treatment is regularly prescribed in RLS. Magnetic resonance imaging studies revealed a deficiency of iron in different areas of the brain and this was confirmed by direct neuro-pathologic demonstration of low levels of iron in the substantia nigra of affected patients. A relation between low serum ferritin and symptoms of RLS and an improvement of RLS symptoms with iron treatment has also been demonstrated. A recently published review concluded that of all known parameters associated with RLS including dopamine, glutamate, serotonin and ferritin levels, the most consistent finding appears to be iron deficiency. Thus, iron replacement is suggested for RLS patients with a ferritin level <75 ng/ml and according to recent clinical practice guidelines intravenous iron is even effective for treatment of moderate to severe RLS in patients with ferritin levels <300 ng/ml.

In our study population of relatively young and healthy but iron deficient blood donors, the frequency of RLS at V0 was 21%, which is higher than the reported prevalence of RLS between 5 and 15% in the general population. This high prevalence in blood donors is comparable to the numbers reported by others (Birgegard et al: 18%, Ulfberg et al: 18%, Burchell et al: 17%). We also compared the severity of self-reported RLS symptoms at baseline (V0) and after iron therapy and found a significant improvement after iron supplementation (p=0.001). These results are consistent with the findings of a double-blind, placebo-controlled study by Wang et al. where a statistically significant improvement in RLS patients with low serum ferritin levels (15-75 ng/ml) after oral iron treatment was demonstrated.

4.2. Fatigue

All domains of reported fatigue symptoms in our study indicated a significant improvement after iron treatment (p<0.001). In contrast to our findings, two Swiss randomized controlled trials in blood donors did not show a clinical benefit by either oral or intravenous iron supplementation. However, Waldvogel et al. supplemented 80 mg oral iron per day for only 4 weeks and Fontana et al. gave 800 mg intravenous iron once but no detailed results have yet been published. In line with our results, a recent review including 18 trials enrolling 1170 non–anemic iron deficient adults found that iron supplementation led to a reduction of fatigue. Furthermore a meta-analysis reported that iron may be effective in reducing fatigue in iron deficient patients without anemia.

4.3. Quality of sleep
Sleep disorders often arise as a consequence of or in combination with RLS\textsuperscript{5, 6, 39, 49}. In our study, we evaluated the quality of sleep with the Jenkins Sleep Evaluation Questionnaire and classified the answers with the Jenkins Scale\textsuperscript{37}. All 4 items: difficulty falling asleep, waking up several times per night, difficulty staying asleep, and waking up feeling tired and worn out after usual amount of sleep showed a clear and significant improvement after iron therapy. Our results support previous findings that in iron deficient individuals with sleep disorders, iron therapy improves symptoms\textsuperscript{5, 6}.

4.4. Other symptoms

Unspecific symptoms including pica, brittle nails, hair loss and a plain tongue were reported more often before than after iron therapy (statistically nonsignificant). In the literature, the association of iron deficiency with these symptoms also remains controversial\textsuperscript{15, 16, 54, 55}. Pica is not considered specific for iron deficiency\textsuperscript{56, 57}. However, pica for ice responds rapidly to treatment with iron\textsuperscript{57}. Bryant et al. found a significantly higher percentage of pica among blood donors with iron deficiency (11%) compared to iron sufficient donors (4%). Furthermore, pica symptoms resolved completely with oral iron supplements\textsuperscript{18}. In our analysis we found a nonsignificant improvement after iron supplementation but only 6% of participants reported pica before and 3% after iron therapy.

Headache, dyspnea and dizziness improved significantly in our study. However, this may also be explained with the high percentage of anemic blood donors after the last blood donation and before iron therapy (73% of women and 82% of men) with a mean Hb of 11.7 g/dl and with the higher mean Hb of 13.6 g/dl after iron supplementation\textsuperscript{32}. Interestingly, there was no difference between IV and oral iron therapy and the attained ferritin concentration at visit 1, although our study was certainly underpowered for such analyses.

4.5. Strengths and limitations

Strengths of our study are the selective inclusion of iron deficient blood donors, the excellent compliance and the low number of participants lost to follow up.

However, our study has some limitations: first, it was performed in a single European academic institution. Second, the follow up was limited to 3 months. Third, questionnaires are subjective and fourth, and most importantly, we did not include a placebo group. Therefore, we were unable to assess the natural course of current clinical practice (not using any iron supplements) and the influence of the hemoglobin increase per se. However, the very high incidence of iatrogenic anemia at baseline (75%) and a recent RCT\textsuperscript{58} suggest that the recovery to pre-donation hemoglobin concentrations and iron stores typically takes substantially longer than the whole blood inter-donation interval.

5. Conclusions

Our findings support the hypothesis that iron deficiency can cause clinically relevant subjective symptoms in otherwise healthy, iron deficient blood donors and that these symptoms may be improved by iron treatment. Our study was relatively small for the evaluation of clinical endpoints. The fact that we were able to see a significant improvement in several of the analyzed clinical symptoms suggests that benefits outweigh potential risks of iron treatment and is of clinical relevance. Interestingly, the approach of iron substitution (oral or IV) was not crucial for the improvement of symptoms. Therefore, blood donation services should identify donors at risk for iatrogenic iron deficiency and offer iron supplementation accompanied by the extension of the donation interval to maintain the health of each blood donor, especially in premenopausal women, the highest risk group.
**Author Contributions:** Conceptualization, Camilla Drexler and Karin Amrein; Data curation, Susanne Macher; Formal analysis, Magdalena Holter; Funding acquisition, Karin Amrein; Investigation, Susanne Macher, Cornelia Herster, Martina Moritz and Camilla Drexler; Methodology, Susanne Macher, Camilla Drexler and Karin Amrein; Project administration, Susanne Macher, Cornelia Herster, Martina Moritz and Camilla Drexler; Resources, Tatjana Stojakovic, Thomas Pieber and Peter Schlenke; Supervision, Susanne Macher; Validation, Eva Maria Matzhold; Visualization, Eva Maria Matzhold; Writing – original draft, Susanne Macher and Karin Amrein; Writing – review & editing, Eva Maria Matzhold, Peter Schlenke and Camilla Drexler.

**Acknowledgments** We appreciate the support of all participating blood donors, and the nurses of the apheresis unit under the lead of S. Sipurzynski and C. Meißl. We further thank I. Lindenau and M. Schröck for operative support.

**Conflicts of Interest:** KA has received speaker and advisory board fees from Vifor Pharma and Fresenius Kabi. The study was supported by Vifor Pharma, Austria and G.L. Pharma, Austria.
References

1. Diaz JR, de las Cagigas A, Rodriguez R. Micronutrient deficiencies in developing and affluent countries. Eur J Clin Nutr 2003;57 Suppl 1:S70-2.
2. Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014;123(5):615-24.
3. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341(26):1986-95.
4. Earley CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004;5(3):231-5.
5. Kryger MH, Otake K, Foerster J. Low body stores of iron and restless legs syndrome: a correctable cause of insomnia in adolescents and teenagers. Sleep Med 2002;3(2):127-32.
6. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep 1998;21(4):371-7.
7. Koo BB, Bagai K, Walters AS. Restless Legs Syndrome: Current Concepts about Disease Pathophysiology. Tremor Other Hyperkinet Mov (N Y) 2016;6:401.
8. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003;160(2):221-36.
9. Verdon F, Burmand B, Stubi CL, Bonard C, Graff M, Michaud A, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. Bmj 2003;326(7399):1124.
10. Houston BL, Hurrie D, Graham J, Perija B, Rimmer E, Rabbani R, et al. Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials. BMJ Open 2018;8(4):e019240.
11. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011;118(12):3222-7.
12. Pollitt E. Iron deficiency and cognitive function. Annu Rev Nutr 1993;13:521-37.
13. Carter RC, Jacobson JL, Burden MJ, Armony-Sivan R, Dodge NC, Angelilli ML, et al. Iron deficiency anemia and cognitive function in infancy. Pediatrics 2010;126(2):e427-34.
14. Hereberg S, Preziosi P, Galan P. Iron deficiency in Europe. Public Health Nutr 2001;4(2B):537-45.
15. Ghaffari S, Pourafkari L. Koilonychia in Iron-Deficiency Anemia. The New England journal of medicine 2018;379(9):e13.
16. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol 2002;27(5):396-404.
17. Spencer BR, Kleinman S, Wright DJ, Glynn SA, Rye DB, Kiss JE, et al. Restless legs syndrome, pica, and iron status in blood donors. Transfusion 2013;53(8):1645-52.
18. Bryant BJ, Yau YY, Arceo SM, Hopkins JA, Leitman SF. Ascertainment of iron deficiency and depletion in blood donors through screening questions for pica and restless legs syndrome. Transfusion 2013;53(8):1637-44.
19. Germain M, Delage G, Robillard P, Katz LM, Gregoire Y. The association between frequency of blood donation and the occurrence of low birthweight, preterm delivery, and stillbirth: a retrospective cohort study. Transfusion 2016;56(11):2760-7.
20. Conrad ME, Crosby WH, Jacobs A, Kaltwasser JP, Nusbacher J. The Hippocratin principle of 'primum nil nocere' demands that the metabolic state of a donor should be normalized prior to a subsequent donation of blood or plasma. How much blood, relative to his body weight, can a donor give over a certain period, without a continuous deviation of iron metabolism in the direction of iron deficiency? Vox Sang 1981;41(5-6):336-43.
21. Page EA, Coppock JE, Harrison JF. Study of iron stores in regular plateletpheresis donors. Transfusion medicine 2010;20(1):22-9.
22. Semmelrock MJ, Raggam RB, Amrein K, Avian A, Schallmoser K, Lanzer G, et al. Reticulocyte hemoglobin content allows early and reliable detection of functional iron deficiency in blood donors. Clin Chim Acta 2012;413(7-8):678-82.
23. Simon TL. Iron, iron everywhere but not enough to donate. Transfusion 2002;42(6):664.
24. Simon TL, Garry PJ, Hooper EM. Iron stores in blood donors. JAMA : the journal of the American Medical Association 1981;245(20):2038-43.
25. Brittenham GM. Iron deficiency in whole blood donors. Transfusion 2011;51(3):458-61.
26. Cable RG, Glynn SA, Kiss JE, Mast AE, Steele WR, Murphy EL, et al. Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion 2011;51(3):511-22.
27. Finch CA, Cook JD, Labbe RF, Culala M. Effect of blood donation on iron stores as evaluated by serum ferritin. Blood 1977;50(3):441-7.
28. Baart AM, van Noord PA, Vergouwe Y, Moons KG, Swinkels DW, Wiegerinck ET, et al. High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin. Transfusion 2012.
29. Pedrazzini B, Waldvogel S, Vaucher P, Cornuz J, Heinzner R, Tissot JD, et al. Prevalence of restless legs syndrome in female blood donors 1 week after blood donation. Vox Sang 2014;107(1):44-9.
30. Birgegard G, Schneider K, Ulfberg J. High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sang 2010;99(4):354-61.
31. Silber MH, Richardson JW. Multiple blood donations associated with iron deficiency in patients with restless legs syndrome. Mayo Clin Proc 2003;78(1):52-4.
32. Drexler C, Macher S, Lindenauf I, Holter M, Moritz M, Stojakovic T, et al. High-dose intravenous versus oral iron in blood donors with iron deficiency: The IronWoMan randomized, controlled clinical trial. Clin Nutr 2019.
33. Macher S, Drexler C, Lindenauf I, Sareban N, Schlenke P, Amrein K. High-dose intravenously administered iron versus orally administered iron in blood donors with iron deficiency: study protocol for a randomised, controlled trial. Trials 2016;17(1):527.
34. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4(2):101-19.
35. Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 2004;27(1):14-23.
36. Vaherla J, Pentti J, Helenius H, Kivimaki M. Sleep disturbances as a predictor of long-term increase in sickness absence among employees after family death or illness. Sleep 2006;29(5):673-82.
37. Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988;41(4):313-21.
38. Chalmers RP. mirt: A multidimensional item response theory package for the R environment. Journal of Statistical Software 2012;48(6):1-29.
39. Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Med 2010;11(1):31-7.
40. Godau J, Klose U, Di Santo A, Schweitzer K, Berg D. Multiregional brain iron deficiency in restless legs syndrome. Mov Disord 2008;23(8):1184-7.
41. Connor JR, Ponnuru P, Wang XS, Patton SM, Allen RP, Earley CJ. Profile of altered brain iron acquisition in restless legs syndrome. Brain 2011;134(Pr 4):959-68.
42. Wang J, O'Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Med 2009;10(9):973-5.
43. Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG, Medical Advisory Board of the Willis-Ekbom Disease F. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc 2013;88(9):977-86.
44. Winkelmann JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2016;87(24):2585-93.
45. Allen RP, Picchietti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 2018;41:27-44.
46. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165(11):1286-92.
47. Hogl B, Kiechl S, Willeit J, Saletu M, Frauscher B, Seppi K, et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 2005;64(11):1920-4.
48. Barriere G, Cazalets JR, Bioulac B, Tison F, Ghorayeb I. The restless legs syndrome. Prog Neurobiol 2005;77(3):139-65.
49. Ulfberg J, Nystrom B. Restless legs syndrome in blood donors. Sleep Med 2004;5(2):115-8.
50. Burchell BJ, Allen RP, Miller JK, Hening WA, Earley CJ. RLS and blood donation. Sleep Med 2009;10(8):844-9.
51. Waldvogel S, Pedrazzini B, Vaucher P, Bize R, Cornuz J, Tissot JD, et al. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. BMC Med 2012;10:8.
52. Fontana S, Jüni P, Niederhauser C, Keller P. Lack Of Effectiveness Of Intravenous Iron Infusion In Healthy Blood Donors With Low Ferritin: A Double-blind Randomized Controlled Trial: p-134. Vox Sanguinis 2014;107:98.
53. Yokoi K, Konomi A. Iron deficiency without anaemia is a potential cause of fatigue: meta-analyses of randomised controlled trials and cross-sectional studies. Br J Nutr 2017;117(10):1422-31.
54. Rushton DH. Management of hair loss in women. Dermatol Clin 1993;11(1):47-53.
55. Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol 2003;121(5):985-8.
56. Simpson E, Mull JD, Longley E, East J. Pica during pregnancy in low-income women born in Mexico. West J Med 2000;173(1):20-4; discussion 5.
57. Rector WG, Jr. Pica: its frequency and significance in patients with iron-deficiency anemia due to chronic gastrointestinal blood loss. J Gen Intern Med 1989;4(6):512-3.
58. Kiss JE, Brambilla D, Glynn SA, Mast AE, Spencer BR, Stone M, et al. Oral iron supplementation after blood donation: a randomized clinical trial. JAMA 2015;313(6):575-83.